The pharma industry has barely had time to lick its wounds from enhanced Medicaid rebates being included in the just-passed COVID relief bill, and now it faces the prospect of more of the same: popular legislation that incorporates price controls.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?